Camp4 Therapeutics(NASDAQ) CAMP

Camp4 Therapeutics makes medicines for rare genetic diseases. They help the body reach healthy protein levels. Their tools focus on the brain and nervous system.

Mapping the Body's Genetic Knobs

• CMP-002: Lead treatment candidate for a severe brain disorder called SYNGAP1; designed to increase essential protein levels in the brain to treat seizures and cognitive issues.
• RAP Platform: Proprietary mapping tool used to find and characterize regulatory RNA sequences that control how genes are expressed.
• CNS Programs: Discovery-stage projects targeting rare diseases within the central nervous system where protein production is too low.

Partnerships and Recent Private Funding

• Entered a research and license agreement with GlaxoSmithKline in December 2025 to develop new treatments in various disease areas.
• Secured $50.1 million through a private placement of common stock and warrants in September 2025.
• Raised $28.1 million in an underwritten offering of common stock in December 2025.
• Partnered with BioMarin Pharmaceutical Inc. in September 2024 for research activities, which concluded in early 2026.
• Closed its initial public offering on October 15, 2024, raising $72.4 million in net proceeds.

What Makes Their Science Different?

The company uses its RAP Platform to identify regulatory RNAs, which act like control switches for gene activity. This technology aims to boost natural protein production rather than using traditional gene replacement methods.

Checking the Recent Financial Health

• Revenue reached $1.3 million in Q1 2026, up 50.8% from $858,000 in Q1 2025.
• Net loss deepened to $18.3 million in Q1 2026, a 47.4% worsening from the $12.4 million loss the previous year.
• Free cash flow hit negative $11 million in Q1 2026, an improvement from negative $14.6 million in Q1 2025.
• Cash and cash equivalents totaled $99.2 million as of March 31, 2026.

The Evolution of Camp4

Camp4 has grown from a discovery startup into a clinical-stage biotech using a specialized RNA platform. Its mix of internal programs and major partnerships provides the capital needed to test its technology in human trials.